- Home
- CNX vs ACLX Comparison
CNX vs ACLX Comparison
Compare CNX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- ACLX
- Stock Information
- Founded
- CNX 1860
- ACLX 2015
- Country
- CNX United States
- ACLX United States
- Employees
- CNX N/A
- ACLX N/A
- Industry
- CNX Oil & Gas Production
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- CNX Energy
- ACLX Health Care
- Exchange
- CNX Nasdaq
- ACLX Nasdaq
- Market Cap
- CNX 4.6B
- ACLX 3.8B
- IPO Year
- CNX 1999
- ACLX 2022
- Fundamental
- Price
- CNX $28.87
- ACLX $71.81
- Analyst Decision
- CNX Hold
- ACLX Strong Buy
- Analyst Count
- CNX 13
- ACLX 14
- Target Price
- CNX $32.08
- ACLX $114.75
- AVG Volume (30 Days)
- CNX 2.2M
- ACLX 523.0K
- Earning Date
- CNX 07-24-2025
- ACLX 08-07-2025
- Dividend Yield
- CNX N/A
- ACLX N/A
- EPS Growth
- CNX N/A
- ACLX N/A
- EPS
- CNX 0.97
- ACLX N/A
- Revenue
- CNX $1,813,319,000.00
- ACLX $56,979,000.00
- Revenue This Year
- CNX $29.36
- ACLX N/A
- Revenue Next Year
- CNX $22.80
- ACLX $108.81
- P/E Ratio
- CNX $29.48
- ACLX N/A
- Revenue Growth
- CNX 35.63
- ACLX N/A
- 52 Week Low
- CNX $25.88
- ACLX $47.86
- 52 Week High
- CNX $41.93
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- CNX 36.04
- ACLX 54.44
- Support Level
- CNX $28.39
- ACLX $66.52
- Resistance Level
- CNX $29.41
- ACLX $73.03
- Average True Range (ATR)
- CNX 0.72
- ACLX 3.23
- MACD
- CNX -0.03
- ACLX -0.16
- Stochastic Oscillator
- CNX 28.16
- ACLX 57.36
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.